Patient Square Capital LP Has $10.51 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Patient Square Capital LP boosted its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 3.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,410,331 shares of the company's stock after purchasing an additional 48,352 shares during the period. EyePoint Pharmaceuticals comprises 3.9% of Patient Square Capital LP's investment portfolio, making the stock its 5th largest position. Patient Square Capital LP owned 2.07% of EyePoint Pharmaceuticals worth $10,507,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Adage Capital Partners GP L.L.C. boosted its holdings in shares of EyePoint Pharmaceuticals by 51.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company's stock worth $42,838,000 after purchasing an additional 1,958,580 shares during the period. Franklin Resources Inc. raised its position in EyePoint Pharmaceuticals by 3.1% during the 4th quarter. Franklin Resources Inc. now owns 4,137,567 shares of the company's stock valued at $30,825,000 after purchasing an additional 125,519 shares during the last quarter. Vanguard Group Inc. lifted its holdings in EyePoint Pharmaceuticals by 24.8% in the 4th quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company's stock worth $28,334,000 after buying an additional 755,045 shares during the period. Federated Hermes Inc. grew its position in shares of EyePoint Pharmaceuticals by 92.7% in the 4th quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company's stock worth $27,620,000 after buying an additional 1,783,765 shares during the last quarter. Finally, TCG Crossover Management LLC increased its stake in shares of EyePoint Pharmaceuticals by 287.3% during the fourth quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company's stock valued at $26,614,000 after buying an additional 2,650,000 shares during the period. Institutional investors own 99.41% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on EYPT shares. HC Wainwright restated a "buy" rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Chardan Capital decreased their price objective on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, StockNews.com raised shares of EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, EyePoint Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $25.29.

EyePoint Pharmaceuticals Trading Up 1.0%

EYPT opened at $5.91 on Wednesday. The company has a market cap of $406.67 million, a price-to-earnings ratio of -2.96 and a beta of 1.58. The stock has a fifty day simple moving average of $5.99 and a two-hundred day simple moving average of $7.45. EyePoint Pharmaceuticals, Inc. has a 12-month low of $3.91 and a 12-month high of $13.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.65). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The company had revenue of $24.50 million during the quarter, compared to analyst estimates of $8.84 million. On average, analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Want to see what other hedge funds are holding EYPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.